Bridging therapy before CAR-T for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of drug called a bispecific antibody as a bridge to keep lymphoma under control while you prepare for CAR-T cell therapy. The goal is to see if this approach is safe and effective for people whose lymphoma has returned or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed type of aggressive B-cell lymphoma that has come back or not responded to at least one prior treatment.
- Your lymphoma cells must have a specific marker called CD19.
- You must be considered a candidate for CAR-T cell therapy by your medical team.
- You must have at least one tumor that shows up on a PET/CT scan.
- You must be generally able to care for yourself (ECOG score 0-2) and have a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.
This study tests a combination of two drugs (golcadomide and rituximab) given as a bridge treatment before CAR-T therapy for people with aggressive B-cell lymphoma that has not responded to prior treatment. The goal is to help control the lymphoma until CAR-T therapy can be given.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.